See which workplaces made this year's list.

2026_GPTW_best-places-by-industry-Manufacturing+Production-GE_HealthCare

Employees say:"I have been working for this company for 5.5 years and I can honestly say that this is a great place to work. I feel seen and heard by my manager and coworkers. My team has a great relationship/bond where we treat each other like family and have each others back. For example, while enduring many &nbsp;organizational changes, I know that my manager has my back and best interest at heart. I feel safe here in knowing that my day to day decisions on how I do my job are valid and backed up."

Best Large Workplaces in Manufacturing and Production

With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

AI is a major force shaping this year’s list—but it’s far from the only story.

World's Most Admired Companies

2025_GPTW_ManufacturingProduction_Large_GE HealthCare_US1__685d54bb4f22a2fc232770e0_3

Employees say:&nbsp;"Though we are a very large, global organization, we collaborate together at the individual level and there is a strong sense of 'one GEHC.' We are clear on our purpose to keep patients and customers at the forefront of what we do and are often reminded about the global impact we are having in health care, regardless of our role. When someone reaches out to me or I reach out to them, I feel there is a strong sense of servant leadership and desire to help. I continue to be amazed at the colleagues I have met across the globe who know me first as a person and secondly as my role—people genuinely enjoy creating relationships across regions, functions, and segments, which makes work fun, enjoyable, and personable!"

Fortune partnered with Great Place to Work to analyze survey feedback representing nearly 62,000 U.S. employees.

Best Workplaces_Chicago_Large_2025-GE HealthCare_US1__67fd6226d94556dd4465c985_3

Employees say:"I have found that at GE HealthCare, this organization is very committed to our values, always keeping our colleagues and patients as the priority and ensuring safety and quality. This is embodied throughout meetings and demonstrated through leaders at all levels. There is a natural strive towards continuous improvement and challenging ourselves and our work to continue to be forward-thinking. It makes the work interesting and exciting, but the best part is that the people here have a mind-set of supporting each other to accomplish the big rocks together and doing it the right way!"

Best Large Workplaces in Chicago

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

Best Workplaces In Chicago

Founded

Sites

Sector

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Best Workplaces In Manufacturing And Production

Industry Vertical

GE HealthCare designs, manufactures, and services advanced medical technology, diagnostics, and digital health solutions. The company’s roots go back to pioneering work with X-ray technology in the late 19th and early 20th centuries. The company is also responsible for the first routine full-body CT scan and key innovations related to MRI and ultrasound scanners. A longtime division and then subsidiary of General Electric, it completed its spinoff as an independent company in January 2023.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

GE HealthCare (GEHC): Company Profile, Stock Price, News, Rankings

legacy

GE HealthCare

ge healthcare

Good day, and thank you for standing by. Welcome to the GE Healthcare second quarter twenty twenty five earnings conference call. At this time, all participants are in a listen only mode. After the speakers' presentation, there'll be a question and answer session. To ask a question during the session, you need to press 11 on your telephone.

You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that this conference is being recorded. I would now like to turn the conference over to your speaker today, Carolyn Borders. Please go ahead.

Thanks, operator. Good morning, and welcome to GE Healthcare's second quarter twenty twenty five earnings call. I'm joined by our President and CEO, Peter Arduini and Vice President and CFO, Jay Ciccaro. Our conference call remarks will include both GAAP and non GAAP financial results. Reconciliations between GAAP and non GAAP measures can be found in today's press release and in the presentation slides available on our website.

During this call, we'll make forward looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties. With that, I'll hand the call over to Peter.

Thanks, Carolyn. Good morning, and thank you all for joining today. I'm pleased to report that we delivered another solid quarter marked by continued business execution, healthy customer demand and ongoing progress with our Precision Care strategy. In the second quarter, we saw orders growth across all segments. Backlog remains at record levels and strong book to bill reflects continued customer investment in capital equipment. For example, we're seeing this in imaging and advanced visualization solutions and for outpatient cardiac and orthopedic settings. We're also observing healthy procedure volumes globally. Revenue growth in the period was driven by strength in The U. S. And EMEA regions.

Looking at commercial execution, I'd like to highlight significant wins and long term enterprise deals that demonstrate our continued momentum. During the second quarter, in The U. S, we secured our largest order ever of Omni Legend PETCT systems. We also entered a strategic collaboration with Ascension valued up to $90,000,000 in the first year. We broadened our long term relationship with one of the largest providers in Mexico and secured a $250,000,000 five year collaboration in Europe.

These strategic collaborations leverage our D3 strategy, which is about bringing to market world class solutions with smart devices and drugs, enabling disease state solutions with digital and AI. Success in our global strategy is evidenced by the adoption of new product introductions, which generated over 50% of our sales. This demonstrates the success of our R and D investments. Our commercial teams go to market with a solutions mindset, clinical expertise and deep product domain. All of this enables us to better serve patient needs and help our customers create sustainable long term growth.

In the quarter, we delivered strong EPS despite a mixed macroeconomic landscape. Overall, we're optimistic given customer investment, our operational execution and increasing clarity in the global trade landscape. Now I'll turn the call over to Jay to provide more details on the quarter. Jay?

Thanks, Pete. Let's start with our financial performance on Slide four. We reported revenues of $5,000,000,000 in the quarter with organic growth of 2% at the high end of our expected range. On a reported basis, service revenue grew 7% driven by global growth in new and existing customer agreements, including enterprise deals. Product revenue was up 2%.

We delivered healthy organic orders growth, up 3% year over year with first half order growth of 7%. Book to bill for the quarter was strong at 1.07 times and we exited the quarter with a record backlog of $21,300,000,000 Backlog was up $2,200,000,000 year over year and was up $700,000,000 sequentially. Adjusted EBIT margin in the quarter was 14.6%, down 80 basis points year over year due to tariff impacts. This was partially offset by lean actions and volume. We continue to execute on our optimization initiatives in line with our medium term profitability goals.

We delivered strong adjusted EPS in the quarter of $1.06 per share, up 6 percent year over year. This included approximately $08 of impact from tariffs. And improved tax rate contributed $07 of benefit year over year. And we also saw lower interest expense. Lastly, free cash flow of $7,000,000 in the quarter was up 189,000,000 versus the prior year.

Taking a closer look at margin performance in the second quarter on slide five, adjusted gross margin declined 180 basis points year over year. This was primarily due to tariff expenses and new product investments. Given the tariff dynamics, we thought it would be helpful to also look at performance in the 2025. Adjusted gross margin for the first half of the year decreased 50 basis points and adjusted EBIT margin decreased 20 basis points, including the impact of tariffs. This was partially offset by productivity and increased volume.

We remain focused on what's in our control, including driving productivity initiatives and implementing tariff mitigation actions. Let's move on to segment performance, starting with Imaging on slide six. Organic revenue in the quarter was up 1% versus the prior year. This was driven by strong execution in EMEA and The U. S, largely offset by China headwinds.

Segment EBIT margin declined 110 basis points year over year, driven by tariff pressure. This was partially offset by productivity improvements. Excluding tariffs, Imaging margin would have increased year over year and sequentially. Overall capital equipment demand and procedure growth remain healthy as customers invest in imaging innovation. Turning to Advanced Visualization Solutions on Slide seven, organic revenue was up 2% year over year with continued strong performance in The U.

S. As customers invest in AI enhanced ultrasound solutions across multiple care settings. Segment EBIT margin increased 20 basis points year over year, driven by productivity and volume. As we look ahead, we expect continued strength in growth markets driven by product launches across the portfolio to accelerate growth and recurring revenue. Turning to Patient Care Solutions on Slide eight, organic revenue was flat year over year.

Growth in Monitoring Solutions was offset by Life Support Solutions, which faced a difficult year over year comparison. This was largely due to the strong backlog conversion in the second quarter of last year. Segment EBIT margin declined two forty basis points, primarily driven by inflation and unfavorable portfolio mix. This was partially offset by productivity actions. We remain focused on new product introductions, including monitoring, anesthesia and labor delivery solutions, which we expect to drive growth and improve margin over time.

Moving to Pharmaceutical Diagnostics on slide nine, we delivered another quarter of solid growth at 5% organically. This was versus a difficult comparison in the 2024 when organic sales grew 14%. EBIT margin declined 200 basis points year over year due to planned U. S. Radiopharmaceutical investments, Nehan metaphysics and FX headwinds, which were partially offset by price.

We remain confident in our growth outlook for PDX, given continued strength in global imaging procedures that drive the need for imaging agents and the consistent growth of radiopharmaceuticals. Let's look at cash performance on Slide 10. We delivered free cash flow of 7,000,000 up $189,000,000 year over year, primarily due to timing. The prior year period reflects our annual employee compensation payments that were paid in the second quarter, but now they are paid in the first quarter. We continue to strategically manage our working capital and monitor inventory cycle times.

Turning to capital allocations, our priorities remain intact. In April, we announced a Board authorized share repurchase program of $1,000,000,000 In the second quarter, we repurchased approximately $100,000,000 of our shares, reflecting our view of strong long term growth opportunities. We also issued $1,500,000,000 in bonds to refinance our November 2025 debt maturity. Additionally, we're focused on investing in organic growth, maintaining our dividend and pursuing strategic M and A that aligns with our portfolio strategy. Turning to slide 11 on tariffs.

As Pete mentioned, we're pleased that the global tariff environment has become clearer since the time of our last earnings call. Today, we're providing an updated adjusted EPS walk that reflects our best view of the gross and net tariff impacts versus our prior guidance. We've made significant progress with mitigating actions and continue to implement these initiatives across the globe. As outlined on the slide, we've continued to make prudent assumptions regarding the bilateral U. S.

And China tariffs, as well as announced tariffs for the EU, Mexico, Canada and Japan. In essence, as we did last quarter, we're only assuming the current agreed upon tariffs. In April, we guided to an adjusted EPS range of $3.9 to $4.1 which reflected $0.85 of total net tariff impact post the significant remediation work performed by our teams. With the easing of tariffs, we expect to realize an improvement of approximately $0.40 from the prior full year adjusted EPS guidance. We also expect a $03 improvement due to commercial execution, tax and interest.

The total net tariff impact in our adjusted EPS guidance for 2025 is now $0.45 In the second quarter, the impact from tariffs was less than $50,000,000 We will continue to drive mitigation actions into 2026 and beyond. As a result, in 2026, we expect less than $0.45 of adjusted EPS impacts from tariffs. Now, let's turn to our full outlook on slide 12. For the full year 2025, reflective of continued positive customer sentiment in many of the global markets we serve and continued business momentum, we're raising our organic revenue growth guidance to approximately 3%. Based on where rates are today, we expect FX to be a 50 basis point tailwind to revenue.

For adjusted EBIT margin, we are now forecasting a range of 15.2% to 15.4% for the full year compared to our previous guidance of 14.2% to 14.4%. Our adjusted effective tax rate is expected to be in the range of 20% to 21% for the full year compared to a range of 21% to 22% in our prior guidance. This compares favorably to 2024 by 80 to 180 basis points, primarily due to the utilization of tax attributes post spin. For adjusted EPS, we now expect between $4.43 and $4.63 for the full year. This is up versus our prior estimate of $3.9 to $4.1 per share.

We now expect to deliver free cash flow of at least $1,400,000,000 for the full year versus our prior expectation of at least $1200000000.0.20 25 will be impacted by tariff payments as previously discussed. To provide additional insight, for the 2025, we currently anticipate year over year organic revenue growth for the quarter to be in the range of 2% to 3%, and we expect adjusted EPS to decline high single digits year over year due to tariff impacts. With that, I'll turn the call back over to Pete. Pete?

Thanks, Jay. As you know, our innovation pipeline is focused on delivering solutions that provide productivity, efficiency, and improved outcomes along the patient journey and across the enterprise. A great example of this is the fast growing sector of nuclear medicine where we play a significant role enabling better care for multiple diseases. In the first half of the year, orders grew strong double digits across our proprietary diagnostic imaging agents and leading molecular imaging solutions made up of AI enabled equipment and digital tools. PET imaging is a core component of nuclear medicine and a cornerstone to precision care.

Recently, one of the largest GPOs reported that PET is expected to outpace other modalities in the coming years, in part due to an aging population and the rise of novel therapeutics. As a result, our customers are looking to GE Healthcare as the partner to help them increase capacity and build infrastructure to better manage their patient flow. We believe our comprehensive offering of nuclear medicine solutions across multiple care areas puts us at an advantage. So let me explain why. In Alzheimer's, momentum began two years ago with the FDA approval of the first amyloid targeting therapies.

Therapies. Since then, we acquired VIM software and have integrated differentiating amyloid assessment and therapy monitoring tools into our devices. We continue to see demand for Visible, our diagnostic pet amyloid agent. And just last month, the FDA updated Visumel's label to allow for quantification of amyloid and patient selection for treatment. It also removes limitations for use for monitoring therapy response and predicting development of dementia.

In oncology, updated guidelines are driving increased use of Suriana scans for certain patients with metastatic breast cancer. Suriana revenues have increased significantly year over year. And meanwhile, MIM continues to be a differentiator for us to drive efficiencies and complex workflows like Theranostics, one of the fastest growing areas of nuclear medicine. We're continuing to advance the commercial ramp up for FERCOTTO. It's now covered by all seven Medicare administrative contractors and included on cardiac pet policies in more than half of the nation's commercially insured population.

At the twenty twenty five Society of Nuclear Medicine and Molecular Imaging annual meeting, a clinical abstract featuring data from Thirpyridaz, the active agent in FERCADA received the Cardiology Abstract of the Year Award. As the world looks to address these devastating diseases, we're confident that our investments thus far and in the future will pay off in the form of real patient impact and customer interest to grow their service lines. Our nuclear medicine approach with smart devices and a portfolio of drugs enabled by digital and AI is a great example of D3 in action. As a partner, we're not only helping customers define the future, but delivering solutions at a time when they're ready to embrace it. As we conclude the call, we're pleased with the orders and revenue performance in the second quarter and in the first half of the year, which has been supported by strong customer demand.

We continue leading in AI and healthcare, topping the FDA's AI enabled medical device list for the fourth year running with 100 authorizations. We help drive clinical confidence, improve productivity for customers and fuel our growth. We're also on track to deliver progress on our innovation pipeline with many of our higher margin products launches planned in the second half of this year and into 2026. Our capital allocation strategy primarily focused on organic and inorganic investment, while also returning cash to shareholders through a dividend and share repurchases demonstrates our financial flexibility. We continue to drive long term value through our strategic priorities with healthy end markets, solid operating execution and a global trade environment that's becoming more clear.

We're pleased to be in a position to raise our 2025 guidance today. I want to thank our teams for another strong quarter of execution and for their relentless focus to deliver for patients and customers globally. Now, let's open up the call for questions.

Thank you, Peter. I'd like to ask participants to please limit yourself to question and one follow-up.

Thank you. Participants limit yourself Our first question comes from Vijay Kumar with Evercore ISI. Your line is open.

Hi, guys. Thanks for taking my question. Congrats on a nice execution here. Maybe my first question here on capital environment. Our math suggests capital book to bill was 1.13, another double digit print here, a really strong print in that first half.

Maybe can you talk about capital environment across different regions, U. S, Europe and whether China's bottoming?

Hey, Vijay, thanks for the question. Yeah, I mean, orders obviously in the first half were about 7% when you take a look across the two. And when we take a look at the different markets around the world, I'll kind of go around the horn. I'd say US, one of the things we've talked about has an aging installed base, particularly in imaging, probably older than many around the world. Some of that with the pauses that took place during COVID.

So there is a robust replacement cycle that's going on. I think that's one aspect of The U. S. The other aspect is many of the new clinical and products that are coming out either on the drug or the device side. I mean, you think of electrophysiology and what's happening in that boom, driving the need for advanced cath labs as an example, or what's happening relative to certain pharmaceuticals and the need for more MR follow-up imaging.

I mean, are just examples that are driving and we see those trends to be robust. The other, which is a big obvious one is the need for productivity. It's difficult for US hospitals to get staff. And so equipment that moves a patient swiftly through the institution with a high quality diagnosis is a very important asset. And hence, when we look at some of the surveys that come out, our most recent capital survey still has a rather bullish view on spending and committing money towards our equipment.

We haven't seen any significant pullbacks, I'd say, in any of the data at this point in time, even from some of the most recent bills that were passed in Washington. So stay tuned on that. Obviously, some of those won't come into effect until maybe '26, but we aren't seeing anything at this point in time. Europe, we're actually seeing some good growth. I would say last year, I'd mentioned that with some government changes, there were pauses, most notably like in The UK and France.

We're actually seeing recovery in geographies there from a capital decision standpoint, UK, Germany. So I think that plays out. Obviously, we'll have to see how the final negotiations take place with some of the tariff bills. Does that affect things? But at this point, we're not seeing a lot.

I think emerging markets, countries like Indonesia, there's a lot of activity going on, in a positive way for us, know as well as other players. And Latin America, we're seeing strong. I'd say China, we're seeing activity pick up, but the market recovery is taking a little bit longer. And so, our focus there is that it's probably still going to take a little bit more time to evolve. We think the longer term outlook will be positive just based on the size of the country, But we have, I'd still say a paced view of how that market will cover. I don't know, Jay, anything you'd add to that?

Yes, sure. Vijay, just as it relates to your specific comment on equipment book to bill, we reported 1.07 times. By the way, this was after 1.09 times in the first quarter and the same number in the fourth quarter. So we're really pleased with this book to bill performance, the strength of the markets that we're experiencing right now. As we look at the as you know with that calculation, we incorporate PDX and service revenue at one to one.

So to your point, equipment book to bill in all three of those quarters was well above 1.1. So I think it's really a good backdrop as we look to accelerate the business over the midterm.

That's helpful comments here. And maybe one follow-up, if I may. Your tariff assumptions, you're mitigating half the impact here in fiscal 'twenty five, noted fiscal 'twenty six impact to be lesser than 'twenty five. Maybe elaborate on the actions the company is taking, or any of these actions, or things that you would call as causing regret if rates were to change, come down, and based on all that you know right now, do we have visibility into high singles EPS for fiscal 'twenty six? Thank you.

Great. Thanks, Vijay. Overall, we're very pleased with the work that the organization is undertaking on tariffs. It's been daily work across the board and a lot of progress over the last several months. As we think about the actions, I would bucket them in two pieces.

The first set are no regrets moves that we immediately implemented. And then the second are longer lead time items where we waited a bit. So let's talk about each piece. In the first bucket, there's things like USMCA exemptions, bonded logistics, simple supplier changes where we have dual sourcing in place. And so all of those activities are things that we benefited from immediately, and we will likely leave in place for the foreseeable future.

The second piece, though, relates to the broader restructuring of the supply chain. And so as we gain clarity on how the final tariff deals look, we're starting to invest in some more substantive changes. For example, shifting manufacturing to more local for local, or working with our supply base to move capacity within their network to more tariff friendly geographies. Those items are longer lead time items. They do require some investment.

But from our standpoint, you don't want to do those kinds of moves until you have clarity on final trade deals. And so as we've seen these trade deals shape up, we're now in a position to begin to execute on some of these, which we'll do in the second half of the year, and then those will benefit 2026. To your point, it's really important that we have 2026 below 2025 impacts. That's a clear area of focus for us as we look to mitigate these things. As far as EPS growth for next year, no comment at this stage.

We'll work through that in the coming months as we put together our plans for 2026. Steve, anything to add?

Yeah, would just say, Vijay, I mean, we've been really all over this one. I think it's gonna set us up well going into '26, but also into '27. Sometimes these events also cause you to really take a deep look at your businesses. And so we're doing a lot of housecleaning as well, configurations, things of that nature. I'll give you an example, our vascular business, we've had a product that's used in orthopedics that was only made in China.

We have the capability to make it in Utah. We'll make them in both locations. And so we can better serve the customers and probably the turnaround time when a customer wants one, we've cut the lead time probably in half with that change. Ultrasound probes, we make them in four different places around the world. Sometimes that was led by one sole decision, maybe cost or something.

As we see where these rates are, we can actually titrate where we wanna make specific ones. So, I would say our customer service out of this as well as resolving it, both of those are going to improve as we just get smarter as we think about the geo landscape of where we want to make and how we provide customer service and support, but also what the costs are associated with.

One moment for our next question. Our next question comes from Joanne Wuensch with Citi. Your line is open.

Good morning, and thank you for taking the question. I want to spend a minute or two talking about the order book. It looks like the order growth decelerated versus the first quarter. Can you help us understand the drivers? Were there any pull forwards in the first quarter?

Or is this a better way to look at this more on a year over year book to bill type of order book? Thank you so much.

Sure. As Pete mentioned earlier, Joanne, we're really pleased with the health of the customer capital environment. We think it's a robust backdrop. Surveys confirm that, and our performance confirms it as well. Second quarter order growth of 3% was certainly below Q1, but we knew that was going to happen.

Book to bill was healthy, as I mentioned moments ago, and we had a record backlog over $21,000,000,000 which really sets us up well heading into next year. We did expect some moderation, as I said, and it's important to look at this not on a quarter basis, but on a period a little bit more extended than that. If you look at the first half orders growth, we're at 7%. I think if you look at the last nine months of orders, we're at 7% or 6%. If you look at the last year, we're at mid single digit growth.

So when we talk about this mid term aspiration of driving mid single digit growth, certainly the performance that we've seen on a three, six, nine, twelve basis all supports that. We're seeing strength in U. S, EMEA, Emerging Markets. Customers are committed to CapEx. So I wouldn't overanalyze the deceleration from Q1 to Q2.

We did have a large customer order in the first quarter that did help the order growth a little bit. But overall, we're encouraged by the environment.

Yeah, and just the only thing I would add, Joanne, is that with capital equipment, it's always gonna be a little bit lumpy by quarter. And the more that we are successful with enterprise deals, where you get a large commitment, we have POs cut in a given quarter for the next eighteen, twenty four months of deliveries. We're gonna put those in right then. We're obviously not gonna spread them out or such, and so that's gonna create lumpiness. And so, as Jay said, the retrospective look is super important there.

But we feel very good about the position where we're in. And obviously, with new products coming after two, three years of investment that we would expect that to accelerate here in future quarters.

One moment for our next question. Our next question comes from Larry Biegelsen with Wells Fargo. Your line is open.

Good morning. Thanks for taking the question. Pete, I wanted to ask about the progress with Flurcato. What feedback are you hearing from customers? What are some of the barriers to adoption that you're addressing?

And how are you feeling about the $30,000,000 in guidance for 2025? And I did have one follow-up.

Okay. Hey, Larry. Thanks for the question. I'll start with the 30. I mean, we feel good about it.

Let me tell you a little bit. It's probably less about the 30 and more the composition of it that positions us for the next two, three, four years in the ramp. But look, we're pleased with the progress and some of the first things are is expanding the manufacturing footprint. Keep in mind, this is a product that we make the API, we make the chemistry labs, but the real actual manufacturing happens at CMOs, contract manufacturing organizations close to the site of delivery. We set a goal that we need to have about 25 this year to meet those numbers.

We're roughly at about 18, so we're actually on track slightly ahead of where we need to be. I think that will help us reach over 90% of the PET imaging sites that we've targeted here by the end of the year. So that's an important characteristic. The other one is, can you pay for it? I'd mentioned earlier the max, all seven in The US, the Medicare administrators are covering.

And now we have over 65% of the commercially insured beneficiaries covering it. I think we'll pick up the other substantial covered lives here in the not too distant future. So from a reimbursement standpoint, feel good that we're on track to that. Building the partnerships and the structures we've always talked about is probably one of the most critical things. It's this training program with the physicians, the techs, clinical applications, even the feedback on reimbursement and billing as this ramps up.

That cycle time, honestly, is one of the most critical things. And today, from when we engage a customer until they get reimbursement and they get the cycle working to pay, takes about ninety days. The reality of it is we need to work on it and we have our lean processes we're looking through with customers. I would get that down to forty or thirty days. When you get to that level of you engage a customer and thirty days later they can be up and running and billing, that's when the real velocity takes up.

We don't need to reach that velocity to get to the targets we have for this year, but we need that velocity to grow these things into 100 plus millions of dollars of growth down the road. So that's the work. The feedback has been fantastic. Hands down, when someone sees the image quality on a product like this versus any of the predicate products out there, particularly on obese patients or older patients, it's really second to none. So that's been great feedback that we've been receiving on it overall.

Super helpful. Jay, the gross margin came in line with our expectations, but was still down about 180 basis points year over year. It looks like tariffs were about an 80 to 90 basis point headwind in the quarter. What are the other factors that impacted the gross margin in the quarter? And how should we think about the gross margin for the rest of the year? Thanks.

Sure. In the second quarter, our gross margin did decline 180 basis points year over year, as you say. And I point to a few drivers on that. The tariffs are about half of the impact. Tariffs came in a little less than $50,000,000 in the quarter, and that was clearly an impact to gross margin.

And then there's a couple other elements in play. And one of them is a bit of reclassification. I shouldn't say reclassification, but good news. We had $25,000,000 shift from R and D to cost of goods sold. If we look at our total engineering and product spending at the company, about 70% of it sits within R and D, and about 30% sits within cost of goods sold.

Of the 30%, it's made up of sustaining engineering, but also programs that pass technical feasibility and are close to launch. And what happened in the second quarter is we had about 50 basis points of impact from programs that shifted from pre technical feasibility to technical feasibility as they approach the launch date. It's a really nice dynamic. Now overall, program and product spending was basically flat in the quarter. So R and D was down 8%, but this dynamic really explains that reduction.

We kind of look at this as a very good piece of news from our standpoint As we think about the continued performance on the pipeline and driving that forward, it was just it was a great performance in the quarter. And so that did in fact negatively impact gross margin by about 50 basis points. The other thing I would say is we had about 50 basis points of impact from in our service business. What happened here is we had some negative mix given the startup costs for new multi vendor service contracts as part of large enterprise wins that we have in place. When you take on the service on day one, the margin is a little bit lower.

And as you convert some of those accounts to more GE Healthcare products, which is really the design, the service margin improves. So in the second quarter, that was a bit of a headwind. But again, as I look at the long term contours of the business, I think it is really good news. Pete, I don't know if you'd add anything to this.

No, I think you covered it, Jay. I think the main thing is when you look at engineering based type programs in R and D, we're spending a significant amount of funds. We're making good progress with the advancements of some of the key programs we spoke about in MR and CT and MI are the reasons that this conversion moving forward, we'll be talking about some of these and launches in future months and quarters. So that's all great, great exciting news. And I think to Jay's point on the service side, the two sides of this, as these enterprise deals evolve, the actual margins increase with them over time because of this phenomena.

And also as we add some of these new products into the contracts that have more AI, have more digital capabilities to capture rate on service and the price to serve actually goes up. And so from a standpoint of total margin dollars contributing, that also has a pretty significant effect, the vitality of products we're selling with the service contract. So feel good about gross margin as you guys know it's a huge focus for us and something we're going to continue to drive.

One moment for our next question. Our next question comes from Robbie Marcus with JPMorgan. Your line is open.

Great. Good morning. Thanks for taking the questions. Two for me. Wanted to start off with China.

What you saw in the quarter? What the environment like, how you're thinking about it for the rest of the year and if there's a ex China growth rate you're willing to give on the rest of the business?

Hey, Robbie, let me start and then maybe I'll turn it over to Jay to give a little bit more details as well. Look, in China, I'd say we're seeing activity pick up. That being said, the velocity obviously of the activity is picking up, but the pace of the recovery itself, meaning actual POs and people buying, is taking a little bit longer. So seeing some uptick in activity, but things are taking a little longer. Tender cycles in particular at the provincial level have kind of extended.

It's just taking a little bit longer to get done. And so I think as we look at the back half of the year, our expectations is that's going to continue. That idea of bid to award is still going to be a little bit longer. So we've reflected a slightly more conservative back half for China into our total company guidance. Obviously, if that does better, we'll do better, but that's kind of how we've taken it.

I'd also say, we're really excited about we brought in a new leader into our China team, Will Song, who has significant multinational experience, local experience, a lot of deep clinical channel work and is bringing some really interesting ideas for us that I think are gonna obviously pay off for the future. And so we've got a lot of new launches that are gonna be coming around the world, but they're really gonna be consequential as well in China in the next eighteen, twenty four months as well. Some of these higher end products that won't be part of different tenders, they'll stand alone. So we're excited about those as well. Jay, what would you add here?

Well, the first half in China did come in better than our expectations. And I think really what it came down to in the second quarter, we had better than expected backlog conversion. We are expecting and modeling some softness in the second half versus the first half. Really, this is an unpredictable market as we've seen. And we're sort of reflecting a cautious view as we watch continued progress in tenders and awards.

Our 3% outlook for the total company has a range of outcomes for China. So we're not counting on any meaningful step up at this point. And we're kind of having that muted outlook for China as we consider the second half of the year. But as look at this overall, the market's still large, and we still believe it will be an important growth driver going forward.

Great. Jay, that's a perfect segue into my follow-up question. You had a fairly in line second quarter versus The Street on organic sales growth. You raised the 2025 forecast a bit. How should we think about the cadence for the rest of the year?

China is going down a little bit in that guide. What gives you the confidence in moving it higher? What's driving it? Thanks.

Yes. I think, Robbie, we feel very good about the second half and full year guidance for a couple of reasons. And a lot of this relates to the strong performance that we've seen in the last several quarters on order growth, on book to bill and on backlog. All of these things are at, in some cases, record levels, but we've seen really robust performance overall. And so as we think about the cadence, first half organic revenue about 3%.

The third quarter guidance, we've guided to 2% to 3%. The fourth quarter is typically our seasonally strongest quarter. We're expecting a little bit faster than the two to three and the three to four range as we look at it. And so overall, I think it's a really nice story and it sets up well as we look for really building on that acceleration into next year. The one thing I will say is we do a lot of work in terms of looking at when deals are going to be delivered.

And so a lot of our work in terms of secured rate revenue analysis allows us to forecast reasonably well the future quarters. And so I would say that we're increasingly confident and it sits on the back of this robust capital environment that we've seen and that we've been able to capitalize on over the last several months. I'll remind you, some of those deals from the first quarter, some of the orders related to imaging and other equipment, they take six, nine, twelve or even longer in terms of delivery date. So that supports this acceleration that we're seeing in the second half.

One moment for our next question. Our next question comes from David Roman with Goldman Sachs. Your line is open.

GE HealthCare (GEHC) Q2 2025 Earnings Call Transcript

Company Participants